Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iDOSE: Dietary Salt and Eczema Severity
NCT07447063Phase 4Recruiting
- Sponsor
- University of California, San Francisco
- Start
- Aug 2026
- Primary completion
- Mar 2028
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial (2 arms), sponsored by University of California, San Francisco. Primary endpoint: Eczema severity at 6 months. Started Aug 2026; status: recruiting.
Beyond the preview
Go deeper on NCT07447063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07447063.